Briquilimab

N/A

Report date: 2024/09/11 16:17:58

Base Information

Drug NameBriquilimab
Drug Alias NameAMG-191JSP-191JSP191
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptor
Therapy Area/IndicationsImmunologic Deficiency SyndromesChronic UrticariaSevere Combined Immunodeficiency +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen IncNational Heart, Lung And Blood InstituteStanford University
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteNational Heart, Lung, And Blood Institute (Nhlbi)National Institute Of Allergy And Infectious Diseases (Niaid) +[4] 
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency SyndromesChronic UrticariaGranulomatous Disease, Chronic +[5] 
Inactive IndicationsSevere Combined ImmunodeficiencyMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksDrugBank